Clinical Trial Update: A 5-Year Postmarketing Safety Study Of Xalcom In Patients With Open Angle Glaucoma Or Ocular Hypertension [Phase 3]

View source ↗

Summary

This document reports the completion of a 5-year postmarketing safety study of Xalcom in patients with open-angle glaucoma or ocular hypertension (Phase 3).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ocular Hypertension
• Open-angle Glaucoma

Drugs mentioned

• Xalcom

Snippet

Sponsor: Pfizer | Conditions: Glaucoma, Open-Angle, Ocular Hypertension | Phase 3 | Status: COMPLETED